Invetech

David Hodl, Head, Business Development, Cell Therapy
Melbourne, Australia
(NYSE: FTV)
Invetech helps cell and gene therapy developers to visualize, strategize, and manage the future. With proven processes, expert insights and full-spectrum services, the company swiftly accelerates life-changing therapies from clinical to commercial-scale manufacturing. With configurable technology platforms and automated production systems, Invetech enables predictable, reproducible products of the highest quality and efficacy. The company’s integrated approach brings together biological scientists, engineers, designers, and program managers to deliver successful market offerings to more people globally. Working in close collaboration with early-stage and mature life science companies, Invetech is committed to advancing the next generation of vital, emerging therapies to revolutionize healthcare and precision medicine. www.invetechgroup.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions